Close Menu

NEW YORK (GenomeWeb News) – Asuragen said today that it will work with Biogen Idec to develop a companion diagnostic test for a cancer drug.

Asuragen will use its RNA technologies to develop an assay that could help select which patients will benefit from a drug candidate that Biogen Idec now has in clinical development.

The Austin, Texas-based Asuragen currently offers its Signature Genetic Testing and Oncology Testing product lines, as well as its Armored RNA technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.